Secondary transplantation of spleen cells from Δ¹²-PGJ₃–treated recipients showing the absence of leukemia. Panels A through C represent secondary transplantation of CD45.1⁺ BCR-ABL mice treated with Δ¹²-PGJ₃ or vehicle control transplanted into CD45.2 recipient mice. Panels D and E represent FV-LSCs from Δ¹²-PGJ₃ or vehicle control–treated mice transplanted into secondary BALB/c-Stk^−/− recipients. (A) Spleen morphology (top left), spleen weight (bottom left), and WBC counts of mice after secondary transplantation that received donor cells from vehicle-treated or Δ¹²-PGJ₃–treated donor cells (right). (B) Flow cytometric analysis of spleen cells from secondary transplantations. Cells were gated on GFP⁺ and the expression of Kit and Sca1 are shown. (C) Analysis of donor CD45.1 expression in spleen cells. (D) Spleen morphology (top left), spleen weight (bottom left), and WBC counts of mice after secondary transplantation that received donor cells from vehicle-treated or Δ¹²-PGJ₃–treated donor cells (right). (E) Flow cytometric analysis of spleen cells from secondary transplantations. Cells are gated on M34⁺ and the expression of Kit and Sca1 is shown.